Ladostigil hydrochloride (TV-3326), an orally active compound, acts as a dual inhibitor targeting both cholinesterase and brain-selective monoamine oxidase (MAO), demonstrating inhibition constants (IC50s) of 31.8 μM for acetylcholinesterase (AChE) and 37.1 μM for MAO-B. This compound exhibits neuroprotective, antioxidant, and anti-inflammatory properties, making it useful for research into depression and Alzheimer's disease.